OverviewSuggest Edit

DURECT began life in 1998 dedicated to exploiting the benefits of enhanced drug delivery. Our goal was to optimize the physical, pharmacokinetic, and pharmacodynamic properties of approved active agents in ways that would solve significant clinical problems. In recent years, we have built upon this significant legacy, expanding our reach to encompass the development of a family of endogenous molecules that are entirely new to pharmaceutical research and that show remarkable promise in a number of important therapeutic areas.

Whether taking aim at improved drug formulations or bringing to market therapies based on completely novel molecules and avenues of research, the men and women of DURECT strive to fulfill a fundamental promise to patients, physicians, corporate partners, and investors: create best-in-class pharmaceutical products with enduring value—measured most directly by their potential to make real, palpable differences in the lives of those who need them.

TypePublic
HQCupertino, US
Websitedurect.com

Latest Updates

Employees (est.) (Feb 2020)90(+3%)
Revenue (FY, 2019)$29.6 M(+60%)
Share Price (Nov 2020)$1.8 (+8%)
Cybersecurity ratingAMore

Key People/Management at Durect

James E. Brown

James E. Brown

President and Chief Executive Officer
David R. Hoffmann

David R. Hoffmann

Chairman of the Board
David J. Ellis

David J. Ellis

Vice President, Clinical Development
Terrence F. Blaschke

Terrence F. Blaschke

Director
John W. Gibson

John W. Gibson

Vice President, Birmingham Operations and Principal Scientist
Gail M. Farfel

Gail M. Farfel

Director
Show more

Durect Office Locations

Durect has an office in Cupertino
Cupertino, US (HQ)
DURECT, 10260 Bubb Rd
Show all (1)

Durect Financials and Metrics

Durect Revenue

Embed Graph
View revenue for all periods
Durect's revenue was reported to be $29.56 m in FY, 2019
USD

Revenue (Q3, 2020)

2.7m

Gross profit (Q3, 2020)

1.6m

Gross profit margin (Q3, 2020), %

60.3%

Net income (Q3, 2020)

(9.3m)

EBIT (Q3, 2020)

(8.9m)

Market capitalization (24-Nov-2020)

371.8m

Closing stock price (24-Nov-2020)

1.8

Cash (30-Sept-2020)

18.7m

EV

377.0m
Durect's current market capitalization is $371.8 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

33.5m53.1m15.3m19.4m19.1m14.0m49.2m18.6m29.6m

Revenue growth, %

27%(1%)(27%)

Cost of goods sold

4.7m4.7m4.8m5.7m3.9m5.3m6.6m4.3m4.1m

Gross profit

28.8m48.4m10.5m13.7m15.2m8.7m42.5m14.3m25.4m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

8.9m11.2m7.8m2.7m3.6m5.4m29.4m31.6m34.9m

Accounts Receivable

3.4m2.2m2.3m2.1m2.2m1.2m2.4m1.8m2.3m

Prepaid Expenses

1.8m2.3m1.9m1.0m3.1m3.1m2.2m1.5m

Inventories

3.3m3.4m3.5m3.6m3.9m3.8m3.2m3.4m3.4m
USDQ2, 2011

Financial Leverage

7.3 x
Show all financial metrics

Durect Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Durect Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Durect Online and Social Media Presence

Embed Graph

Durect News and Updates

UPDATE: Durect stock slides after FDA committee ends meeting with split vote on post-surgical pain treatment

Biopharmaceutical company Durect Corp.'s shares slid 12% in premarket trade Friday, after a U.S. Food and Drug Administration committee ended a meeting to review the company's Posimir treatment for post-surgical pain with a split vote, as six members voted to recommend the treatment and six voted a…

Biopharma Durect shares halted ahead of FDA committee meeting on post-surgical pain treatment

Shares of biopharmaceutical company Durect Corp. were halted Thursday, ahead of a U.S. Food and Drug Administration committee meeting to review Posimir, a treatment for post-surgical pain. The meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) will start at 8 a.m. Eas…

Durect Blogs

DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020

DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020 Content Import Fri, 11/13/2020 - 09:01 DURECT Corporation Announces Additional Safety Data and Efficacy Signals fr…

DURECT Corporation to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chief Medical Officer Dr. Norman Sussman

CUPERTINO, Calif. , Nov. 10, 2020 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that Norman Sussman , MD, FAASLD, newly appointed Chief Medical Officer, will host a webinar on the treatment landscape and unmet medical need in treating patients with alcoholic hepatitis (AH), as

DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of Programs

Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET CUPERTINO, Calif. , Nov. 2, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2020 and provided a corporate update.

DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer

DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer Content Import Mon, 11/02/2020 - 16:03 DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer Nov 02, 2020 This release is a backfill from a News Wire Gener…

DURECT Corporation to Announce Third Quarter 2020 Financial Results and Provide Business Update on November 02, 2020

CUPERTINO, Calif. , Oct. 27, 2020 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that it will report third quarter 2020 financial results and host a conference call after the market close on Monday, November 2, 2020. Monday, November 2 @ 4:30pm Eastern Time   / 1:30 p.m.

DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event "Covid-19 Therapeutics in Development"

CUPERTINO, Calif. , Oct. 26, 2020 /PRNewswire/ -- DURECT Corporation  (Nasdaq: DRRX) today announced that it will partipate in the ROTH Capital Healthcare Event, " Covid-19 Therapeutics in Development ," taking place on Wednesday, October 28, 2020 .  The ROTH Healthcare and Biotechnology team are
Show more

Durect Frequently Asked Questions

  • Who are Durect key executives?

    Durect's key executives are James E. Brown, David R. Hoffmann and David J. Ellis.

  • How many employees does Durect have?

    Durect has 90 employees.

  • What is Durect revenue?

    Latest Durect annual revenue is $29.6 m.

  • What is Durect revenue per employee?

    Latest Durect revenue per employee is $328.5 k.

  • Who are Durect competitors?

    Competitors of Durect include Circassia, Avid Bioservices and Affimed N.V..

  • Where is Durect headquarters?

    Durect headquarters is located at DURECT, 10260 Bubb Rd, Cupertino.

  • Where are Durect offices?

    Durect has an office in Cupertino.

  • How many offices does Durect have?

    Durect has 1 office.